The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

Johnson & Johnson is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales ...

After decades of a diversified healthcare business model, Johnson & Johnson has announced it plans to split off its consumer health division from its pharma and medical device operations.

Johnson & Johnson’s Kenvue is to be its specialist Consumer Health division, separate from the company’s pharma and medical device operations. Indeed, Kenvue will apparently be guided by the ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC's Squawk on the ...

From new leadership to product launches, here are five key updates from spine and orthopedic devicemakers since Jan. 15.